Cuprina Holdings Regains Nasdaq Compliance
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Cuprina Holdings announced that on June 11 it has regained compliance with Nasdaq.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CUPR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CUPR
About CUPR
Cuprina Holdings (Cayman) Limited is a biomedical and biotechnology company, which is engaged in the development and commercialization of products for the management of chronic wounds, as well as operating in the health and beauty sector. Its segments include Maggot Debridement Therapy Product (MDT) and Cosmeceutical Product. It manufactures and distributes a line of medical grade sterile blowfly larvae bio-dressing products marketed under the MEDIFLY brand name, or the MEDIFLY products. The MEDIFLY products are used as a biological debridement tool for chronic wounds, in a procedure known as MDT, which is an effective alternative to surgical debridement. It has two lines of chronic wound care products in its pipeline, such as Collagen dressings, including sponges, particles and hydrogels utilizing bullfrog collagen derived from the valorization of abattoir waste streams of American bullfrogs (Lithobates catesbeianus) and products utilizing medical leeches for wound treatment.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Cuprina Secures FDA Approval for New Maggot Therapy Product
- FDA Approval: Cuprina's MEDIFLY Maggots received FDA 510(k) clearance for treating non-healing necrotic skin and soft tissue wounds, including pressure ulcers and neuropathic foot ulcers, marking a significant advancement in the company's wound care portfolio.
- Market Dominance: Cuprina holds exclusive commercial rights to both maggot species, Lucilia sericata and Lucilia cuprina, allowing the company to strategically choose products based on market familiarity, thereby enhancing its expansion capabilities in Asia and the Middle East.
- Stock Surge: Following the FDA approval, Cuprina's shares (CUPR) soared over 150% on Monday, reflecting strong investor confidence in the company's growth potential, despite a 79% decline in stock value over the past year.
- Retail Sentiment Shift: According to Stocktwits, retail sentiment on CUPR shifted from 'bullish' to 'extremely bullish' in the last 24 hours, indicating heightened market interest and positive expectations surrounding the company's new product.
See More
Biotech Stocks Show Significant Pre-Market Activity
- Significant Pre-Market Gains: SL Science Holding Ltd. (SLBT) surged 200% to $10.00 in pre-market trading, indicating strong market demand and investor confidence, which may attract further capital inflows.
- Active Small-Cap Performers: CervoMed Inc. (CRVO) rose 25% to $3.09, while CAMP4 Therapeutics Corp. (CAMP) increased by 10% to $4.37, reflecting optimistic investor sentiment regarding growth potential in the biotech sector.
- Pre-Market Decliners: Cuprina Holdings (CUPR) fell 30% to $5.89, signaling market concerns about its future prospects, which could lead investors to reassess their investment strategies.
- Increased Market Volatility: The commencement of trading on Nasdaq, along with management news and proposed offerings, has heightened overall market sentiment volatility, prompting investors to approach potential market risks with caution.
See More
Cuprina Secures FDA Clearance for MEDIFLY, Shares Surge Over 110%
- FDA Approval: Cuprina Holdings' wholly-owned subsidiary Cuprina Pte. Ltd. received 510(k) clearance from the FDA for MEDIFLY Maggots in wound debridement, marking a significant advancement in the biomedical sector.
- Market Reaction: Following the announcement, Cuprina's shares surged over 110% in Monday's trading, closing at $8.41, reflecting strong investor confidence and the market potential of the new product.
- Technological Advantage: MEDIFLY Maggots utilize Lucilia cuprina maggots, offering a biological, non-antibiotic alternative for wound healing, particularly for chronic non-healing wounds like diabetic foot ulcers and pressure injuries, which is expected to enhance patient treatment outcomes.
- International Expansion Potential: The FDA clearance will facilitate further regulatory approvals in markets such as Saudi Arabia, Hong Kong, and mainland China, enhancing Cuprina's global market competitiveness and business growth potential.
See More
Regentis Soars After Withdrawing US Listing Application
- Regentis Stock Surge: Regentis Biomaterials Ltd. (RGNT) saw its shares soar over 500% to close at $9.40 after withdrawing its Form F-1 registration with the SEC, indicating strong market confidence in its strategic decision.
- GelrinC Product Development: The company's lead product, GelrinC, has received CE Mark approval in Europe, with plans to initiate surgeon training in Q3 2026, which is expected to enhance its market readiness and competitive positioning.
- Cuprina FDA Approval: Cuprina Holdings (CUPR) received FDA clearance for its MEDIFLY maggots used in wound debridement therapy, leading to a stock increase of over 100%, reflecting its innovative potential and market demand in the medical field.
- Intellia Positive Results: Intellia Therapeutics (NTLA) jumped over 20% following positive phase 3 results for its hereditary angioedema treatment, with plans for a BLA submission targeting FDA approval in the first half of 2027, showcasing its strong prospects in the biopharmaceutical sector.
See More
Cuprina Secures FDA 510(k) Clearance for MEDIFLY Maggots™
- FDA Clearance Milestone: Cuprina Holdings' wholly-owned subsidiary, Cuprina Pte. Ltd., has received FDA 510(k) clearance for MEDIFLY Maggots™, marking it as the first Lucilia cuprina maggot debridement product to achieve this status, representing a significant advancement in chronic wound care.
- Significant Market Potential: MEDIFLY Maggots™ is specifically designed for the debridement of non-healing necrotic skin and soft tissue wounds, expected to provide new treatment options for wound care providers in the U.S., addressing the growing demand for chronic wound management.
- Dual-Species Advantage: Cuprina holds FDA commercial rights for both Lucilia sericata and Lucilia cuprina, allowing flexibility to offer the most suitable treatment based on market needs, thereby enhancing the company's competitive position across various regions.
- International Expansion Opportunities: The FDA clearance paves the way for MEDIFLY Maggots™ registration in other markets such as Saudi Arabia, Hong Kong, and mainland China, which is anticipated to accelerate the company's global business expansion and market penetration.
See More
Cuprina Holdings Regains Nasdaq Compliance
- Compliance Restoration: Cuprina Holdings announced on June 11, 2026, that it has regained compliance with Nasdaq Capital Market listing requirements, eliminating the delisting risk due to its stock price falling below $1, thus ensuring continued trading of its shares.
- Delisting Notification: Previously, the company received a delisting notice from Nasdaq after its stock price fell below $1 for 30 consecutive trading days, failing to regain compliance within 180 days, prompting the company to request a hearing to contest the decision.
- Hearing Cancellation: With Nasdaq's Listing Qualifications staff confirming the company's compliance, the previously scheduled hearing for July 7, 2026, has been canceled, a decision that is expected to boost investor confidence and stabilize the stock price.
- Growth Outlook: CEO David Quek stated that the company will continue to drive growth in multiple biomedical sectors, including chronic wound management and medical waste recycling, reflecting a positive outlook for future development.
See More
Cuprina Secures FDA Approval for New Maggot Therapy Product
- FDA Approval: Cuprina's MEDIFLY Maggots received FDA 510(k) clearance for treating non-healing necrotic skin and soft tissue wounds, including pressure ulcers and neuropathic foot ulcers, marking a significant advancement in the company's wound care portfolio.
- Market Dominance: Cuprina holds exclusive commercial rights to both maggot species, Lucilia sericata and Lucilia cuprina, allowing the company to strategically choose products based on market familiarity, thereby enhancing its expansion capabilities in Asia and the Middle East.
- Stock Surge: Following the FDA approval, Cuprina's shares (CUPR) soared over 150% on Monday, reflecting strong investor confidence in the company's growth potential, despite a 79% decline in stock value over the past year.
- Retail Sentiment Shift: According to Stocktwits, retail sentiment on CUPR shifted from 'bullish' to 'extremely bullish' in the last 24 hours, indicating heightened market interest and positive expectations surrounding the company's new product.
See More
Biotech Stocks Show Significant Pre-Market Activity
- Significant Pre-Market Gains: SL Science Holding Ltd. (SLBT) surged 200% to $10.00 in pre-market trading, indicating strong market demand and investor confidence, which may attract further capital inflows.
- Active Small-Cap Performers: CervoMed Inc. (CRVO) rose 25% to $3.09, while CAMP4 Therapeutics Corp. (CAMP) increased by 10% to $4.37, reflecting optimistic investor sentiment regarding growth potential in the biotech sector.
- Pre-Market Decliners: Cuprina Holdings (CUPR) fell 30% to $5.89, signaling market concerns about its future prospects, which could lead investors to reassess their investment strategies.
- Increased Market Volatility: The commencement of trading on Nasdaq, along with management news and proposed offerings, has heightened overall market sentiment volatility, prompting investors to approach potential market risks with caution.
See More
Cuprina Secures FDA Clearance for MEDIFLY, Shares Surge Over 110%
- FDA Approval: Cuprina Holdings' wholly-owned subsidiary Cuprina Pte. Ltd. received 510(k) clearance from the FDA for MEDIFLY Maggots in wound debridement, marking a significant advancement in the biomedical sector.
- Market Reaction: Following the announcement, Cuprina's shares surged over 110% in Monday's trading, closing at $8.41, reflecting strong investor confidence and the market potential of the new product.
- Technological Advantage: MEDIFLY Maggots utilize Lucilia cuprina maggots, offering a biological, non-antibiotic alternative for wound healing, particularly for chronic non-healing wounds like diabetic foot ulcers and pressure injuries, which is expected to enhance patient treatment outcomes.
- International Expansion Potential: The FDA clearance will facilitate further regulatory approvals in markets such as Saudi Arabia, Hong Kong, and mainland China, enhancing Cuprina's global market competitiveness and business growth potential.
See More
Regentis Soars After Withdrawing US Listing Application
- Regentis Stock Surge: Regentis Biomaterials Ltd. (RGNT) saw its shares soar over 500% to close at $9.40 after withdrawing its Form F-1 registration with the SEC, indicating strong market confidence in its strategic decision.
- GelrinC Product Development: The company's lead product, GelrinC, has received CE Mark approval in Europe, with plans to initiate surgeon training in Q3 2026, which is expected to enhance its market readiness and competitive positioning.
- Cuprina FDA Approval: Cuprina Holdings (CUPR) received FDA clearance for its MEDIFLY maggots used in wound debridement therapy, leading to a stock increase of over 100%, reflecting its innovative potential and market demand in the medical field.
- Intellia Positive Results: Intellia Therapeutics (NTLA) jumped over 20% following positive phase 3 results for its hereditary angioedema treatment, with plans for a BLA submission targeting FDA approval in the first half of 2027, showcasing its strong prospects in the biopharmaceutical sector.
See More
Cuprina Secures FDA 510(k) Clearance for MEDIFLY Maggots™
- FDA Clearance Milestone: Cuprina Holdings' wholly-owned subsidiary, Cuprina Pte. Ltd., has received FDA 510(k) clearance for MEDIFLY Maggots™, marking it as the first Lucilia cuprina maggot debridement product to achieve this status, representing a significant advancement in chronic wound care.
- Significant Market Potential: MEDIFLY Maggots™ is specifically designed for the debridement of non-healing necrotic skin and soft tissue wounds, expected to provide new treatment options for wound care providers in the U.S., addressing the growing demand for chronic wound management.
- Dual-Species Advantage: Cuprina holds FDA commercial rights for both Lucilia sericata and Lucilia cuprina, allowing flexibility to offer the most suitable treatment based on market needs, thereby enhancing the company's competitive position across various regions.
- International Expansion Opportunities: The FDA clearance paves the way for MEDIFLY Maggots™ registration in other markets such as Saudi Arabia, Hong Kong, and mainland China, which is anticipated to accelerate the company's global business expansion and market penetration.
See More
Cuprina Holdings Regains Nasdaq Compliance
- Compliance Restoration: Cuprina Holdings announced on June 11, 2026, that it has regained compliance with Nasdaq Capital Market listing requirements, eliminating the delisting risk due to its stock price falling below $1, thus ensuring continued trading of its shares.
- Delisting Notification: Previously, the company received a delisting notice from Nasdaq after its stock price fell below $1 for 30 consecutive trading days, failing to regain compliance within 180 days, prompting the company to request a hearing to contest the decision.
- Hearing Cancellation: With Nasdaq's Listing Qualifications staff confirming the company's compliance, the previously scheduled hearing for July 7, 2026, has been canceled, a decision that is expected to boost investor confidence and stabilize the stock price.
- Growth Outlook: CEO David Quek stated that the company will continue to drive growth in multiple biomedical sectors, including chronic wound management and medical waste recycling, reflecting a positive outlook for future development.
See More
